Online inquiry

IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1115MR)

This product GTTS-WQ1115MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1115MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5313MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ11750MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ11487MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ15118MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ1702MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ10973MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ169MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ4359MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW